Sialic acids are a family of ␣-keto acids with 9-carbon backbones that are expressed abundantly in animals of the deuterosome lineage (1) . Siglecs (sialic acidbinding immunoglobulin-like lectins) are a family of the sialic acid recognizing lectins that have been recently defined (2) . Members of this family are transmembrane polypeptides with an N-terminal Ig V-set domain, a variable number of C2 set domains, a transmembrane domain and a cytoplasmic tail. The V-set Ig-like domain is the most important in carbohydrate recognition, and the second Ig-like domain may also contribute to the binding (3) .
Among the Siglecs, members of the CD33 subgroup have expanded tremendously during the past few years. Proteins of this subgroup, including Siglec-3, and 5 (4), 6 (5), 7 (6, 7), 8 (8) , 8-L (9), 9 (10, 11) and 10 (12) , share a high degree of sequence homology to Siglec-3, and are clustered on chromosome 19q13.4 just telomeric to the kallikrein family of genes (9, 11, 13) . Also, all members of the CD33-like subgroup possess two characteristic tyrosine-based motifs, with the exception of Siglec-8 (8) . The first of these contains the consensus immunoreceptor tyrosine kinase inhibitory motif (ITIM), and the second motif displays homology to the SLAM (signaling lymphocyte activation molecule) tyrosine-based motif. Using the positional candidate gene approach, we previously identified 3 members of the Siglec family of genes (9, 11 and GenBank Accession No. AF277806). In this paper we describe the cloning of a putative new member of the Siglec family of genes, and describe its genomic structure, chromosomal localization and tissue expression pattern. We also describe three splice variants of this gene, of which two of them are predicted to encode for an active protein.
MATERIALS AND METHODS

Gene prediction programs.
We used a number of computer programs to predict the presence of putative new genes in the genomic area of interest. We initially tested these programs using the genomic sequences of known Siglec genes. The most reliable computer programs, GeneBuilder (gene prediction/exon prediction) (http://l25.itba.mi.cnr.it/ϳwebgene/genebuilder.html), Grail 2 (http://compbio.ornl.gov) and GENESCAN (http://genes.mit.edu/ GENSCAN.html) were selected for further use.
Identification of the new gene.
Through analysis of the chromosomal region 19q13.4, we have previously cloned 3 new genes that belong to the CD33 subgroup of Siglecs (9, 11 and GenBank submission No. AF277806). Overlapping bacterial artificial chromosome (BAC) clones spanning this area were identified by screening of a human BAC library using different radiolabeled gene-specific probes. Restriction digestion analysis and end sequencing were used to align these clones in the proper orientation, by comparing the results with the EcoRI restriction map and the raw sequences of this chromosomal region (available from the Lawrence Livermore National Laboratory, LLNL). A BAC clone that extends more telomerically (BC 799776) from Siglecs 8 and 9 was chosen for further analysis. Initially, we analyzed contigs of linear genomic sequences from this clone, which are available from the LLNL web site, to predict the presence of novel genes. Next, bioinformatic approaches, as previously described (14, 15) , were used to identify a putative new Siglec. The sequence of the putative gene was then verified by different experimental approaches, including sequencing of fragments of this BAC clone, EST database search and PCR screening of tissues, as described below.
Expressed sequence tag (EST) searching. The predicted exons of the putative new gene were subjected to homology search using the BLASTN algorithm (16) on the National Center for Biotechnology Information web server (http://www.ncbi.nlm.nih.gov/BLAST/) against the human EST database (dbEST). Clones with Ͼ98% identity were obtained from the IMAGE consortium (17) through Research Genetics Inc. (Huntsville, AL). The clones were propagated, purified as described elsewhere (18) and sequenced from both directions with an automated sequencer, using insert-flanking vector primers.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
2 g of total RNA was reverse-transcribed into first strand cDNA using the Superscript preamplification system (Gibco BRL). The final volume was 20 l. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequences, different combinations of forward primers (PS-F1, PS-FM, PS-F2) and reverse primers (PS-RU, PS-RM, PS-R1, PS-CR) were used to obtain the full mRNA sequence of the gene (Table 1) . PCR was carried out in a reaction mixture containing 1 l of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 M dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of HotStarTaq DNA polymerase (Qiagen Inc., Valencia, CA) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 95°C for 15 min to activate the Taq DNA polymerase, followed by 40 -45 cycles of 94°C for 30 s, 60 -65°C (depending on primer combinations) for 30 s, 72°C for 1 min and a final extension step at 72°C for 10 min. Equal amounts of PCR products were electrophoresed on 1.5% agarose gels and visualized by ethidium bromide staining. To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, with an automated DNA sequencer.
Tissue expression. Total RNA isolated from 25 different human tissues was purchased from Clontech (Palo Alto, CA). We prepared cDNA as described above for the tissue culture experiments and used it for PCR reactions. Tissue cDNAs were amplified at various dilutions using two gene-specific primers (PS-FM and PS-RM) that recognize both the long and short forms of the gene (Table 1 ). Due to the high degree of homology between Siglecs, and to exclude nonspecific amplification, PCR products were verified by sequencing. Structure analysis. Multiple alignment was performed using the "Clustal X" software package and the multiple alignment program available from the Baylor College of Medicine (Houston, TX). Phylogenetic studies were performed using the "Phylip" software package. Distance matrix analysis was performed using the "NeighborJoining/UPGMA" program and parsimony analysis was done using the "Protpars" program. Hydrophobicity study was performed using the Baylor College of Medicine search launcher. Signal peptide was predicted using the "SignalP" server. Protein structure analysis was performed by "SAPS" (structural analysis of protein sequence) program. Conserved domain search was performed using the "Conserved Domain" (CD) and "ProDom" programs.
RESULTS
Cloning of the Novel Siglec-like Gene (SLG2)
Computer analysis of BAC clone (BC 799776) revealed the presence of a putative novel gene that shows a high degree of homology with other members of the Siglec family of genes. Homology searches, carried out using the BLAST algorithm against the human EST database, revealed the presence of 3 EST clones with Ͼ98% identity with the predicted exons ( Table 2) . These ESTs were obtained, purified and sequenced.
The sequence of the new gene was further confirmed by RT-PCR, using a panel of different tissues as templates.
Genomic Organization of the Siglec-like Gene (SLG2)
The SLG2 gene spans an area of 6,554 bp of genomic sequence on chromosome 19q13.4. The gene is formed of 11 exons and 10 intervening introns. Exon lengths are 37, 384, 285, 48, 270, 48, 258, 285, 94, 112 and 273bp (Fig. 1) . All intron/exon splice sites are closely related to the consensus splice sites (-mGTAAGT . . . CAGm-, where m is any base) (19) .
The open reading frame of the long form of the gene consists of 2094bp, and encodes for a putative 697 amino acid polypeptide with a predicted molecular weight of 76.6 kDa, excluding any posttranslational modifications. The predicted translation initiation codon (ATG) is located at position 1664 (numbers refer to our GenBank submission No. AY029277). The sequences surrounding this start codon match with a Kozak consensus sequence for translation initiation, especially the most highly conserved purine at position Ϫ3 that occurs in 97% in eukaryotic mRNAs (20) . In addition, there is a conserved "C" in position ϩ4, that is found in other members of this family, including Siglecs 5-9 (20) . Furthermore, using this start codon, the resultant protein product shows extensive homology with other members of the CD33-like subgroup of Siglecs (see below). No other initiation codon was found that produced a long, continuous open reading frame.
Structural analysis indicated, like other members of this subgroup, that the SLG2 gene also possesses an N-terminal signal sequence. Using neural networks and hidden Markov models trained on eukaryotes, a cleavage site was predicted between amino acids 16 and 17 (SQA-MD) (Fig. 2) . The presence of a signal sequence is also supported by the hydrophobicity pattern of the protein (Fig. 3) . Conserved Domain (CD) and ProDom searches together with homology alignment indicated the presence of 3 conserved immunoglobulin domains (residues: 27-132, 164 -237 and 370 -443), representing the V-set domain, followed by the 2 C-set domains present in other CD33-like Siglecs (Fig.  4) . In addition, an extra Ig domain, which is formed mainly by exon 5 (amino acid residues 262-341) was identified, representing an extra C-set domain. The single transmembrane domain, predicted by TMpred and also evident in the Kyte-Doolittle hydrophobicity plot (Figs. 3 and 5) , is in keeping with observations for other members of this subgroup. Furthermore, the new putative Siglec contains the two characteristic tyrosine-based motifs, ITIM and SLAM-like, also noted in other members of the CD33-like subgroup of Siglecs (Fig. 4) .
Homology with Other Siglecs
Although the structure of SLG2 is unique, it has a high degree of homology with other members of CD33-like subgroup of Siglecs. At the protein level, it shows 48% identity and 66% similarity with Siglec-5, and 40 -60% similarity with Siglecs 6 -9. Multiple alignment was used to compare the protein sequence of the Siglec-like gene with other members of the CD33-like subgroup and the other Siglec family members. As is evident in Fig. 4 , there is conservation of the key cysteine residues that are responsible for the characteristic folding of the extracellular Ig-like domains in all Siglecs (21, 22) , except for one cysteine at position 170, which might be an alignment artifact because of the presence of another closely located cysteine residue (position 173). The residues believed to be responsible for sialic acid binding, in particular the critical arginine at position 119 and the two aromatic residues at positions 21 and 128 on the A and G strands of the V-set domains (23) , are also conserved in the new gene (Fig. 4) . Multiple alignment indicates that exon 8 of the gene encodes for a unique domain that is highly homologous to a similar domain in the Siglec-5 gene, but was not found in other members of this subfamily of Siglecs.
Phylogenetic Analysis
Phylogenetic analysis was done for all reported human Siglecs using both parsimony and distance matrix methods. Results indicate a close association of the Siglec-like gene SLG2 with other members of the CD33 subgroup of Siglecs (Fig. 6 ). As expected from the high sequence identity mentioned above, the new gene is most closely related to Siglec-5, and shows a somewhat more distant relationship with other, non-CD33, Siglecs.
Splice Variants of the Siglec-like Gene (SLG2)
In our attempts to reveal the full genomic structure of the gene, multiple bands were obtained from some tissues during RT-PCR analysis. Sequencing of these PCR products revealed the presence of two additional splice variants of the gene in addition to the form described above (which is referred to as the "long form" in our GenBank submission). The different splice variants of the gene are represented schematically in Fig.  7 . The short form of the gene is the same as the long form, except for a missing exon 8. Multiple alignment shows that exon 8 is a unique exon that occurs only in the long form of the new gene and the Siglec-5 gene, but not in any of the other members of this siglec subfamily. There is a high degree of sequence homology of this exon in these two genes. Removal of this exon in the short form of the gene results in a smaller predicted protein product that has all the conserved features of this subfamily. In the third splice variant of the gene (splice variant-2, according to our GenBank submission) exons 2 and 3 are combined together with the intronic area in-between, and the same for exons 4 and 5, 7-9, and exon 10 is extended. This form is predicted to encode for a truncated protein of 1086 amino acids.
Tissue Expression
The tissue expression profile for the three splice forms of the SLG2 gene was elucidated by performing RT-PCR using total RNA from 25 normal human tissues. The long form of the gene was found to be relatively highly expressed in bone marrow, spleen, spinal cord, brain, colon and small intestine. Lower expression was apparent in a few other tissues (Fig. 8) . The short form was expressed mainly in the bone marrow, spinal cord, spleen and brain, but at lower levels compared with the long form. Splice variant-2 was expressed mainly in the small intestine and to a lower degree in a few other tissues (Fig. 8) .
Mapping and Chromosomal Localization of SLG2
Restriction digestion analysis of three overlapping BAC clones spanning the chromosomal region 19q13.4 enabled us to precisely locate the relative position of the SLG2 gene in relation to other Siglecs in the region (Fig. 9) . Also, guided by the EcoRI restriction map of the region available from the LLNL, the three BAC clones were aligned in the correct orientation, and thus we were able to establish the direction of transcription of all known Siglec genes in this area. The new gene is transcribed from the telomere towards the centromere, and is located 34,702 bp more centromeric to Siglec-8, which is transcribed in the same direction. Another newly identified Siglec gene (GenBank Accession No. AF277806) is located 32,925 bp further telomerically and transcribed in the same direction. On the centromeric side, Siglec-9 is the closest gene to the new Siglec, separated by 278 kb and running on the oppo- BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS site direction, followed by KLK14 (a member of the kallikrein family of genes) (24) which is located 43,187 bp more centromeric to Siglec-9.
DISCUSSION
The positional candidate cloning is a new approach for gene discovery that combines the knowledge of map position with the increasingly dense human transcript maps and the available expressed sequence tags (ESTs) (25) . Using this approach, we were able to clone a new putative Siglec gene.
Although experimental evidences are lacking, this gene likely represents a new member of the expanding CD33-like subgroup of Siglecs. As is evident in Fig. 4 , the predicted protein contains all the structural characteristics possessed by other CD33-like Siglecs discovered so far. It has the distinctive distribution of cysteine residues found in all Siglecs, necessary for the unique folding pattern of their Ig-like domains (21, 22) . There is also conservation of key amino acids involved in sialic acid binding, specifically the conserved arginine and the two aromatic residues on the A and G strands of the V-set domains (23) .
The cytoplasmic tyrosine-based motifs, ITIM and SLAM-like, found in all other members of the CD33-like subgroup of Siglecs, are also present in our putative member of this subgroup. These motifs have been the focus of investigations in order to elucidate the functional role of these Siglecs within the cell. The primary emphasis has been on the ITIM motif, which has been found to be involved in recruitment of the tyrosine phosphatases SHP1 and 2, and the inositol phosphatases SHIP1 and 2 (26 -28) . Siglec7, originally identified as a natural killer cell inhibitory receptor, was found to recruit the tyrosine phosphatase SHP1 following tyrosine phosphorylation of its ITIM motif,
FIG. 6.
Dendrogram of the predicted phylogenetic tree for human siglec proteins using the UPGMA method. As expected, the tree grouped the CD33-like group of siglecs together. Siglec-5 is the most related protein to the Siglec-like gene (SLG2). leading to the inhibition of natural killer cell cytotoxicity (29) . In addition, CD33 has also been found to recruit SHP1 and 2, both in vitro and in vivo, as a result of phosphorylation of the tyrosine in its ITIM motif (30) . Further, mutation of this tyrosine results in increased red blood cell binding by CD33-expressing COS cells. More recently, it has been reported that engagement of Siglec-7 and CD33 with monoclonal antibodies results in the inhibition of proliferation of both normal and leukemic myeloid cells in vitro (31) . Although Siglec-7 was initially thought to be expressed exclusively in natural killer cells, it has also been found in myeloid cells, at a later stage of differentiation than CD33. The observed inhibitory effects are believed to be the result of phosphorylation of the ITIM motif present in the cytoplasmic domains of both CD33 and Siglec-7. These findings suggest that recruitment of SHP1 and SHP2 by members of the CD33-like subgroup of Siglecs may serve to: (i) inhibit the activating signaling pathways that lead to cell proliferation and survival; and (ii) to modulate the receptor's ligandbinding activity (30) .
More supportive evidence that this new gene is a member of the CD33-like subfamily of Siglecs comes from the chromosomal localization of the gene. As is the case with other members of this subfamily, the new gene is located in the chromosomal region 19q13.4 in close proximity to Siglecs-8, 9 and SLG (Fig. 9) . Interestingly, this chromosomal region harbors a large number of other hematopoitically expressed Ig superfamily members. These include a family of genes encoding killer cell inhibitory receptors expressed on natural killer cells and subsets of T-lymphocytes and immunoglobulin-like transcripts (ILT-1, 2 and 3) expressed on myeloid cells (32) . An emerging theme for these receptors is that they are involved in either stimulatory or inhibitory signalling functions in hematopoietic cells. Our tissue expression results indicate that the gene is expressed, at the mRNA level, in a variety of tissues; high levels of expression are found in tissues where the hemopoietic cell lineage are found, e.g., spleen and bone marrow. This is consistent with the expression patterns of other members of the Siglec-3-like subgroup of Siglecs. In addition, the EST clone that was found to encode for the long form was isolated from B-cells.
The removal of intervening RNA sequences (introns) from the pre-messenger RNA in eukaryotic nuclei is a major step in the regulation of gene expression (33) . RNA splicing provides a mechanism whereby protein isoform diversity can be generated and the expression of particular proteins with specialized functions can be restricted to certain cell or tissue types during development (33) . The sequence elements in the pre-mRNA at the 5Ј and 3Ј splice sites in metazoans have very loose consensus sequence; only the first and the last two bases (GT . . . AG) of the introns are highly conserved (18) . These sequences cannot be the sole determinants of splice site selection, since identical, but not ordinarily active, consensus sequences can be found within both exons and introns of many eukaryotic genes. Other protein factors and sequences downstream of the splice sites are also involved.
Here, we describe the isolation of 2 additional splice variants of the Siglec-like gene SLG2 (in addition to the long form). The existence of multiple splice forms is not unpreceeded among Siglecs. We have recently isolated a long splice-variant of Siglec-8 (9) , and also a Siglec-like gene, SLG, with two splice variants (GenBank Accession No. AF277806).
A major challenge for the future will be to elucidate the function of the CD33-like subgroup of sialic acid binding receptors and to determine the significance of sialic acid binding.
